Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2B | P67870 | 14/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029816 | 0.91 | EPHX2 (0.39) | CSNK2B | |
| SCHEMBL2029819 | 0.91 | EPHX2 (0.39) | CSNK2B | |
| SCHEMBL1934502 | 0.91 | CSNK2B (0.43) | CSNK2B | |
| SCHEMBL1934500 | 0.91 | CSNK2B (0.43) | CSNK2B | |
| SCHEMBL12644795 | 0.91 | CSNK2B (0.43) | CSNK2B | |
| SCHEMBL18405457 | 0.87 | CSNK2B (0.38) | CSNK2BSYK | |
| SCHEMBL6926664 | 0.86 | CSNK2B (0.47) | CSNK2B | |
| SCHEMBL1934731 | 0.86 | CSNK2B (0.47) | CSNK2B | |
| SCHEMBL17641208 | 0.86 | CSNK2B (0.38) | CSNK2B | |
| SCHEMBL6925474 | 0.86 | CSNK2B (0.38) | CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509602-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | Cylene Pharmaceuticals, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011068667-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |